KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Net Cash Flow: 2019-2024

Historic Net Cash Flow for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Dec 2024 value amounting to $205.0 million.

  • Recursion Pharmaceuticals' Net Cash Flow rose 377.72% to $131.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $218.8 million, marking a year-over-year increase of 469.36%. This contributed to the annual value of $205.0 million for FY2024, which is 229.85% up from last year.
  • Recursion Pharmaceuticals' Net Cash Flow amounted to $205.0 million in FY2024, which was up 229.85% from -$157.9 million recorded in FY2023.
  • Recursion Pharmaceuticals' Net Cash Flow's 5-year high stood at $264.1 million during FY2022, with a 5-year trough of -$157.9 million in FY2023.
  • Moreover, its 3-year median value for Net Cash Flow was $205.0 million (2024), whereas its average is $103.7 million.
  • Per our database at Business Quant, Recursion Pharmaceuticals' Net Cash Flow surged by 837.02% in 2022 and then tumbled by 159.79% in 2023.
  • Recursion Pharmaceuticals' Net Cash Flow (Yearly) stood at $192.0 million in 2020, then plummeted by 85.32% to $28.2 million in 2021, then spiked by 837.02% to $264.1 million in 2022, then crashed by 159.79% to -$157.9 million in 2023, then skyrocketed by 229.85% to $205.0 million in 2024.